PURPOSE: To identify potential correlates of cancer-related fatigue (CRF) after curative breast cancer (BC) treatment. The hypothesis was that fatigue would be more severe among women treated with cardiotoxic drugs, with poor physical condition and those who exercised less. METHODS: Observational cross-sectional design. Fatigue was evaluated through PERFORM Questionnaire (multi-item, multi-dimensional). Patient-reported assessments and objective information regarding clinical data, physical activity (PA) and physical condition were analysed as potential correlates of CRF. RESULTS: One hundred eighty women who remained free of disease were recruited. The prevalence of fatigue interfering with quality of life was 43%. Weight, resting and recovery heart rate were positively associated with fatigue. Age and time from diagnosis were negatively associated. Previous therapies, objectively assessed weekly PA, cardiorespiratory condition, muscular strength and adherence to Mediterranean diet were not associated with CRF. CONCLUSIONS: CRF is a prevalent problem after BC treatment. Objectively assessed PA, cardiorespiratory fitness and muscular strength did not predict CRF. The association of heart rate and fatigue deserves a further insight. Future research should include longitudinal studies and determination of biomarkers. IMPLICATIONS FOR CANCER SURVIVORS: BC survivors, especially younger and overweight women, should be informed about fatigue as a potential persistent symptom through all stages of the cancer trajectory and into survivorship. They also should be routinely screened for CRF.
PURPOSE: To identify potential correlates of cancer-related fatigue (CRF) after curative breast cancer (BC) treatment. The hypothesis was that fatigue would be more severe among women treated with cardiotoxic drugs, with poor physical condition and those who exercised less. METHODS: Observational cross-sectional design. Fatigue was evaluated through PERFORM Questionnaire (multi-item, multi-dimensional). Patient-reported assessments and objective information regarding clinical data, physical activity (PA) and physical condition were analysed as potential correlates of CRF. RESULTS: One hundred eighty women who remained free of disease were recruited. The prevalence of fatigue interfering with quality of life was 43%. Weight, resting and recovery heart rate were positively associated with fatigue. Age and time from diagnosis were negatively associated. Previous therapies, objectively assessed weekly PA, cardiorespiratory condition, muscular strength and adherence to Mediterranean diet were not associated with CRF. CONCLUSIONS: CRF is a prevalent problem after BC treatment. Objectively assessed PA, cardiorespiratory fitness and muscular strength did not predict CRF. The association of heart rate and fatigue deserves a further insight. Future research should include longitudinal studies and determination of biomarkers. IMPLICATIONS FOR CANCER SURVIVORS: BC survivors, especially younger and overweight women, should be informed about fatigue as a potential persistent symptom through all stages of the cancer trajectory and into survivorship. They also should be routinely screened for CRF.
Entities:
Keywords:
Breast cancer; Cancer survivors; Cancer-related fatigue; Cardiorespiratory fitness; Heart rate; Physical activity
Authors: Jennifer M Jones; Karin Olson; Pamela Catton; Charles N Catton; Neil E Fleshner; Monika K Krzyzanowska; David R McCready; Rebecca K S Wong; Haiyan Jiang; Doris Howell Journal: J Cancer Surviv Date: 2015-04-16 Impact factor: 4.442
Authors: Mogens Groenvold; Morten Aagaard Petersen; Ellen Idler; Jakob Bue Bjorner; Peter M Fayers; Henning T Mouridsen Journal: Breast Cancer Res Treat Date: 2007-01-03 Impact factor: 4.872
Authors: Jeff A Sloan; H Liu; D V Satele; S Puttabasavaiah; J S Kaur; J Hubbard; A Dueck; P J Stella; Jasvinder A Singh Journal: Trends Cancer Res Date: 2017
Authors: Xin Shelley Wang; Fengmin Zhao; Michael J Fisch; Ann M O'Mara; David Cella; Tito R Mendoza; Charles S Cleeland Journal: Cancer Date: 2014-02-01 Impact factor: 6.860
Authors: H J G Abrahams; M F M Gielissen; I C Schmits; C A H H V M Verhagen; M M Rovers; H Knoop Journal: Ann Oncol Date: 2016-03-02 Impact factor: 32.976
Authors: H F Dorland; F I Abma; S K R Van Zon; R E Stewart; B C Amick; A V Ranchor; C A M Roelen; U Bültmann Journal: J Cancer Surviv Date: 2018-02-05 Impact factor: 4.442
Authors: Mei Rosemary Fu; Melissa L McTernan; Jeanna M Qiu; Christine Miaskowski; Yvette P Conley; Eunjung Ko; Deborah Axelrod; Amber Guth; Tamara J Somers; Lisa J Wood; Yao Wang Journal: Integr Cancer Ther Date: 2022 Jan-Dec Impact factor: 3.077